Cardiovascular Risk Assessment and Laboratory Evaluation in Erectile Dysfunction

Risk Assessment

Erectile dysfunction serves as an early marker for systemic cardiovascular disease, typically appearing about three years before overt coronary artery disease symptoms. (American Urological Association) 1
The Princeton Consensus Conference classifies erectile dysfunction as an independent predictor of future cardiac events, with a risk magnitude comparable to cigarette smoking or a family history of myocardial infarction. (American Urological Association) 1
Men with erectile dysfunction have a markedly increased risk of coronary, cerebrovascular, and peripheral vascular disease; this risk is further amplified by co‑existing obesity and borderline hypertension. (American Urological Association) 1

The 2018 AUA guideline prioritizes measurement of hemoglobin A₁c and a fasting lipid panel as the only routine serum studies likely to influence erectile dysfunction management; other laboratory tests are not routinely indicated. (American Urological Association) 1
Ordering hemoglobin A₁c and a fasting lipid panel should be performed immediately after initiating phosphodiesterase‑5 inhibitor therapy in men with erectile dysfunction and metabolic risk factors. (American Urological Association) 1
Counseling on lifestyle modification—including weight reduction, smoking cessation (if applicable), increased physical activity, and dietary changes—is recommended to address obesity and overall cardiovascular risk. (American Urological Association) 1
If diabetes or clinically significant dyslipidemia is identified, referral to primary care or cardiology is advised for comprehensive management of these conditions. (American Urological Association) 1

Serum total testosterone should be measured in all men presenting with erectile dysfunction to screen for testosterone deficiency; however, gonadotropins (LH, FSH) are only indicated after a confirmed low testosterone result to differentiate primary from secondary hypogonadism. (American Urological Association) 1
In patients with preserved libido, measurement of LH and FSH is not indicated because hypogonadism is unlikely. (American Urological Association) 1
Assessment of morning total testosterone is recommended only if libido declines or if phosphodiesterase‑5 inhibitor therapy fails, as hypogonadism can diminish treatment efficacy. (American Urological Association) 1

Step 1: Order hemoglobin A₁c and fasting lipid panel. (American Urological Association) 1
Step 2: Initiate phosphodiesterase‑5 inhibitor therapy. (American Urological Association) 1
Step 3: Provide lifestyle counseling (weight loss, smoking cessation, exercise, diet). (American Urological Association) 1
Step 4: Consider testosterone testing if clinical indicators arise. (American Urological Association) 1
Step 5: Refer to primary care or cardiology when diabetes or significant dyslipidemia is detected. (American Urological Association) 1

Skipping cardiovascular screening (hemoglobin A₁c and lipid panel) in men with erectile dysfunction and metabolic risk factors misses a critical opportunity to prevent myocardial infarction or stroke. (American Urological Association) 1
Ordering extensive hormonal panels (LH, FSH, prolactin) without first confirming low testosterone leads to unnecessary resource use and delays appropriate care. (American Urological Association) 1
Assuming erectile dysfunction is purely psychogenic in middle‑aged, obese men with hypertension overlooks the predominance of organic etiologies in this population. (American Urological Association) 1

PDE5 inhibitors, such as sildenafil, vardenafil, and tadalafil, are the recommended first-line oral therapy for erectile dysfunction in diabetic patients with hypertension, according to the American Diabetes Association 2, 3
These medications work by delaying cGMP degradation, leading to decreased intracellular calcium levels, producing smooth muscle relaxation in corpus cavernosum and enhancing blood flow resulting in erection during sexual stimulation, as reported by the European Association of Urology 4
Meta-analyses demonstrate that PDE5 inhibitors improve erectile dysfunction in diabetic men without increasing cardiovascular adverse events, with a moderate to high strength of evidence 3
The efficacy of PDE5 inhibitors is independent of diabetes duration, glycemic control, and microvascular complications, as stated by the American College of Cardiology 3

PDE5 inhibitors are contraindicated in patients taking nitrates, which is an important consideration in patients with cardiovascular disease, according to the European Society of Cardiology 3
Cardiovascular risk assessment should be performed before initiating treatment for erectile dysfunction, with a high strength of evidence, as recommended by the American Heart Association 5
Patients at high cardiovascular risk should be stabilized by cardiological treatment before sexual activity is considered or erectile dysfunction treatment is recommended, as stated by the American College of Cardiology 5

Evaluate cardiovascular risk factors and categorize patient as low, intermediate, or high risk, using a validated risk assessment tool, as recommended by the European Society of Cardiology 5
Review current medications for potential contributors to ED, such as diuretics and beta-blockers, and consider alternative treatments, as suggested by the American Diabetes Association 6
For low to intermediate risk patients, start with PDE5 inhibitor, such as tadalafil 5 mg daily or 10-20 mg on-demand, with a moderate strength of evidence 3
Consider lifestyle modifications, including weight loss for obese patients, and optimize glycemic control and manage cardiovascular risk factors, as recommended by the American Heart Association 3, 5

Autonomic neuropathy is associated with a 5.0 times increased risk of erectile dysfunction in diabetic patients with hypertension 7
Poor glycemic control is associated with a 2.3 times increased risk of erectile dysfunction in diabetic patients with hypertension 7
Duration of diabetes is associated with a 2.0 times increased risk of erectile dysfunction in diabetic patients with hypertension 7
Hypertension is associated with a 2.1 times increased risk of erectile dysfunction in diabetic patients with hypertension 7
Diabetic complications, such as nephropathy, retinopathy, and peripheral neuropathy, are associated with an increased risk of erectile dysfunction in diabetic patients with hypertension 7
The prevalence of erectile dysfunction among diabetic men varies from 35-90% 7
Diabetes increases the risk of erectile dysfunction by approximately 4-fold compared to the general population 7

Improving glycemic control can reduce the risk and severity of erectile dysfunction in diabetic patients with hypertension 7